[Successful VEP-IFN-alpha therapy in a case of non-secretory plasma cell leukemia (BJ-kappa type)]

Rinsho Ketsueki. 1994 Jun;35(6):562-8.
[Article in Japanese]

Abstract

Plasma cell leukemia is a rare disorder with poor prognosis. We present a case of non-secretory primary plasma cell leukemia (Bence-Jones kappa type), which was treated successfully by VEP-IFN-alpha therapy. A 82-year old man was admitted to Kanazawa Medical University in May 1991, because of emaciation and dehydration. Clinical findings showed decreased level of gamma-globulin (IgG, IgA and IgM were all decreased markedly), hypercalcemia, renal dysfunction and increased serum beta-2 microglobulin. The peripheral blood leukocyte count was 30,100/microliters with 64% plasma cells, and 80.4% plasma cells were also observed in the bone marrow. Only light chain-kappa was detected in plasma cells by an immunohistochemical staining method, but immunoelectrophoresis showed no M-bow either in serum or urine. Electron microscopy revealed typical plasma cells with prominently developed rough endoplasmic reticulum. From these results, the diagnosis of non-secretory primary plasma cell leukemia was established. He was treated with VEP-IFN-alpha regimen, and plasma cells decreased markedly in both peripheral blood and bone marrow. Serum immunoglobulin recovered to within the normal range. After 6 courses of VEP-IFN-alpha, complete remission was achieved and the remission was maintained until he died of an unrelated event, bronchial obstruction due to misswallowing, in April 1992.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Etoposide / administration & dosage
  • Humans
  • Immunoglobulin Light Chains / analysis
  • Immunoglobulin kappa-Chains / analysis
  • Interferon-alpha / administration & dosage*
  • Leukemia, Plasma Cell / therapy*
  • Male
  • Prednisolone / administration & dosage
  • Vindesine / administration & dosage

Substances

  • Immunoglobulin Light Chains
  • Immunoglobulin kappa-Chains
  • Interferon-alpha
  • Etoposide
  • Prednisolone
  • Vindesine

Supplementary concepts

  • VEP protocol